| Literature DB >> 30684072 |
Zoltán Tóth1, Anikó Kurali2, Ágnes M Móricz3, Attila Hettyey2.
Abstract
Possessing toxins can contribute to an efficient defence against various threats in nature. However, we generally know little about the energy- and time-demands of developing toxicity in animals, which determines the efficiency of chemical defence and its trade-off with other risk-induced phenotypic responses. In this study we examined how immersion into norepinephrine solution inducing the release of stored toxins, administration of mild stress mimicking predator attack or simple handling during experimental procedure affected the quantity and number of toxin compounds present in common toad (Bufo bufo) tadpoles as compared to undisturbed control individuals, and investigated how fast toxin reserves were restored. We found that total bufadienolide quantity (TBQ) significantly decreased only in the norepinephrine treatment group immediately after treatment compared to the control, but this difference disappeared after 12 h; there were no consistent differences in TBQ between treatments at later samplings. Interestingly, in the norepinephrine treatment approximately half of the compounds characterized by >700 m/z values showed the same changes in time as TBQ, but several bufadienolides characterized by <600 m/z values showed the opposite pattern: they were present in higher quantities immediately after treatment. The number of bufadienolide compounds was not affected by any treatments, but was positively related to TBQ. Our study represents the first experimental evidence that toxin quantities returned to the original level following induced toxin release within a very short period of time in common toad tadpoles and provide additional insights into the physiological background of chemical defence in this model vertebrate species.Entities:
Keywords: Bufadienolides; Chemical defence; Hormonal treatment; Stress response; Tadpoles; Toxin production
Mesh:
Substances:
Year: 2019 PMID: 30684072 PMCID: PMC6477007 DOI: 10.1007/s10886-019-01045-9
Source DB: PubMed Journal: J Chem Ecol ISSN: 0098-0331 Impact factor: 2.626
Test statistics and significance of the investigated explanatory variables from the fitted models on the number of bufadienolide compounds (NBC) and total bufadienolide quantity (TBQ)
| Dependent variable | Model type | Random effect (family) | Explanatory variables |
| df | |
|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
| |||
| Treatment | 1.75 | 3 | 0.626 | |||
| Sampling × Treatment | 17.31 | 18 | 0.502 | |||
|
|
|
|
|
|
|
|
|
|
|
|
| |||
|
|
|
|
| |||
|
|
|
|
| |||
|
|
|
|
| |||
| Dry mass | 0.75 | 1 | 0.388 |
Final models are shown in bold; test statistics and P-values for the non-significant predictors were computed by including them one by one into the final models. Random effects are given in SD ± 95% confidence interval
asquare-root transformed
Fig. 1Mean of the total bufadienolide quantity (TBQ) at various sampling occasions. The error bar indicates SE calculated from biological replicates (n = 10 tadpoles in each treatment-sampling combination). Tukey post hoc test performed within each sampling occasion showed that immediately after the application of treatments (0 h) TBQ was significantly lower than in any of the other treatments (all P ≤ 0.003; see also in Table 2)
Pairwise comparisons of the different treatments within each sampling occasion from the LMM fitted on TBQ
| Sampling | Contrast | Estimate | s.e.m. | df | ||
|---|---|---|---|---|---|---|
| 0 hr | Control - Handling | −7.83 | 5.78 | 242 | −1.36 | 0.528 |
|
|
|
|
|
|
| |
| Control - Stress | −2.54 | 6.43 | 242 | −0.40 | 0.979 | |
|
|
|
|
|
|
| |
| Handling - Stress | 5.29 | 6.50 | 242 | 0.81 | 0.848 | |
|
|
|
|
|
|
| |
| 12 hrs | Control - Handling | 1.12 | 5.76 | 242 | 0.19 | 0.997 |
| Control - Norepinephrine | −1.34 | 7.10 | 242 | −0.19 | 0.998 | |
| Control - Stress | −3.94 | 6.42 | 242 | −0.61 | 0.927 | |
| Handling - Norepinephrine | −2.46 | 7.14 | 242 | −0.34 | 0.986 | |
| Handling - Stress | −5.06 | 6.50 | 242 | −0.78 | 0.864 | |
| Norepinephrine - Stress | −2.60 | 7.71 | 242 | −0.34 | 0.987 | |
| 24 hrs |
|
|
|
|
|
|
| Control - Norepinephrine | −11.10 | 7.08 | 242 | −1.57 | 0.400 | |
| Control - Stress | −8.12 | 6.42 | 242 | −1.26 | 0.586 | |
| Handling - Norepinephrine | 4.59 | 7.15 | 242 | 0.64 | 0.918 | |
| Handling - Stress | 7.57 | 6.53 | 242 | 1.16 | 0.653 | |
| Norepinephrine - Stress | 2.97 | 7.69 | 242 | 0.39 | 0.980 | |
| 48 hrs | Control - Handling | 2.48 | 5.77 | 242 | 0.43 | 0.973 |
| Control - Norepinephrine | 2.00 | 7.07 | 242 | 0.28 | 0.992 | |
| Control - Stress | 6.21 | 6.42 | 242 | 0.97 | 0.768 | |
| Handling - Norepinephrine | −0.49 | 7.16 | 242 | −0.07 | 1.000 | |
| Handling - Stress | 3.73 | 6.50 | 242 | 0.57 | 0.940 | |
| Norepinephrine - Stress | 4.21 | 7.69 | 242 | 0.55 | 0.947 | |
| 72 hrs | Control - Handling | −6.08 | 5.75 | 242 | −1.06 | 0.716 |
| Control - Norepinephrine | −9.75 | 7.08 | 242 | −1.38 | 0.515 | |
| Control - Stress | −3.86 | 6.47 | 242 | −0.60 | 0.933 | |
| Handling - Norepinephrine | −3.67 | 7.14 | 242 | −0.51 | 0.956 | |
| Handling - Stress | 2.22 | 6.52 | 242 | 0.34 | 0.986 | |
| Norepinephrine - Stress | 5.89 | 7.70 | 242 | 0.76 | 0.870 | |
| 96 hrs |
|
|
|
|
|
|
| Control - Norepinephrine | −4.72 | 7.07 | 242 | −0.67 | 0.909 | |
| Control - Stress | −8.03 | 6.42 | 242 | −1.25 | 0.595 | |
| Handling - Norepinephrine | 10.96 | 7.14 | 242 | 1.53 | 0.418 | |
| Handling - Stress | 7.65 | 6.50 | 242 | 1.18 | 0.641 | |
| Norepinephrine - Stress | −3.31 | 7.69 | 242 | −0.43 | 0.973 | |
| 120 hrs | Control - Handling | −1.32 | 5.75 | 242 | −0.23 | 0.996 |
| Control - Norepinephrine | −5.14 | 7.07 | 242 | −0.73 | 0.886 | |
| Control - Stress | −0.23 | 6.43 | 242 | −0.04 | 1.000 | |
| Handling - Norepinephrine | −3.82 | 7.14 | 242 | −0.54 | 0.950 | |
| Handling - Stress | 1.09 | 6.50 | 242 | 0.17 | 0.998 | |
| Norepinephrine - Stress | 4.91 | 7.70 | 242 | 0.64 | 0.920 |
P-values were calculated using tukey HSD adjustment; estimates and SE values are expressed on the transformed (Square-Root) scale. Significant contrasts are shown in bold
Estimates and SE values on contrasts of individual bufadienolide compounds’ quantity between the norepinephrine and other treatment groups immediately and 12 hrs after treatment, expressed on the transformed scale
| Compound | m/z value | Sampling | Control - Norepinephrine | Handling - Norepinephrine | Norepinephrine - Stress |
|---|---|---|---|---|---|
| Unidentified compound 2a | 367 | 0 hr |
|
|
|
| 12 hrs | −0.40 | 0.70 | −1.19 | ||
| Unidentified compound 5b | 417 | 0 hr |
| −0.24 |
|
| 12 hrs | −0.10 | −0.09 | −0.04 | ||
| Bufotalinc | 445 | 0 hr |
|
|
|
| 12 hrs | −14.38 | −13.77 | −7.95 | ||
| Unidentified compound 7a | 571 | 0 hr |
|
| 2.54 |
| 12 hrs | −1.11 | −1.01 | 0.44 | ||
| Unidentified compound 8a | 573 | 0 hr |
|
| 2.98 |
| 12 hrs | 0.99 | 0.91 | −1.27 | ||
| Unidentified compound 11 | 715 | 0 hr |
|
|
|
| 12 hrs | 147.15 | 55.36 | −443.82 | ||
| Unidentified compound 12a | 715 | 0 hr |
|
|
|
| 12 hrs | 1.97 | −0.97 | −4.61 | ||
| Unidentified compound 13 | 727 | 0 hr |
|
|
|
| 12 hrs | −4.72 | −199.50 | −44.17 | ||
| Unidentified compound 14a | 729 | 0 hr |
|
|
|
| 12 hrs | −0.92 | −1.96 | −0.70 | ||
| Unidentified compound 15 | 729 | 0 hr |
|
|
|
| 12 hrs | −54.86 | −97.59 | 103.55 | ||
| Unidentified compound 18 | 757 | 0 hr |
|
|
|
| 12 hrs | −67.91 | −118.22 | −92.87 |
Only compounds with amounts that were significantly affected by the sampling × treatment interaction in the fitted lmms are included in the Table. P-values were calculated using tukey HSD tests; significant contrasts are shown in bold
asquare-root transformed
blog-transformed
crank-transformed